Aerosol formulations for buccal and pulmonary application
US6436367B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 17, 1999 |
| Grant date | Aug 20, 2002 |
| Priority date | — |
| Expiry date | Feb 17, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation. The propellant, e.g. a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.